APA (7th ed.) Citation

Macchini, M., Garralda, E., Fiedler, W., Del Conte, G., Rolling, C., Kebenko, M., . . . Ochsenreiter, S. (2020). 98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. European Journal of Cancer, 138, S5. https://doi.org/10.1016/S0959-8049(20)31083-2

Chicago Style (17th ed.) Citation

Macchini, M., et al. "98LBA Late Breaking - Results from the Primary Analysis of a 30 Patient Extension of the GATTO Study, a Phase Ib Study Combining the Anti-MUC1 Gatipotuzumab (GAT) with the Anti-EGFR Tomuzotuximab (TO) or Panitumumab in Patients with Refractory Solid Tumors." European Journal of Cancer 138 (2020): S5. https://doi.org/10.1016/S0959-8049(20)31083-2.

MLA (9th ed.) Citation

Macchini, M., et al. "98LBA Late Breaking - Results from the Primary Analysis of a 30 Patient Extension of the GATTO Study, a Phase Ib Study Combining the Anti-MUC1 Gatipotuzumab (GAT) with the Anti-EGFR Tomuzotuximab (TO) or Panitumumab in Patients with Refractory Solid Tumors." European Journal of Cancer, vol. 138, 2020, p. S5, https://doi.org/10.1016/S0959-8049(20)31083-2.